AG-881
Showing 1 - 25 of 500
Healthy Volunteers Trial in Tempe (AG881 Formulation 1, AG881 Formulation 2, Omeprazole)
Completed
- Healthy Volunteers
- AG881 Formulation 1
- +2 more
-
Tempe, ArizonaCelerion
Jul 20, 2021
Healthy Male Participants Trial in Madison (AG-881, [13C315N3]AG-881)
Completed
- Healthy Male Participants
- AG-881
- [13C315N3]AG-881
-
Madison, WisconsinCovance Clinical Research Unit Inc.
Oct 22, 2019
Primary Immunodeficiency Diseases (PID) Trial (TAK-881)
Not yet recruiting
- Primary Immunodeficiency Diseases (PID)
- TAK-881
- (no location specified)
Oct 4, 2023
Primary Immunodeficiency Diseases (PID) Trial (TAK-881, HYQVIA)
Not yet recruiting
- Primary Immunodeficiency Diseases (PID)
- TAK-881
- HYQVIA
- (no location specified)
Feb 23, 2023
Healthy Volunteers Trial in Hialeah (TAK-881)
Completed
- Healthy Volunteers
- TAK-881
-
Hialeah, FloridaClinical Pharmacology of Miami
Apr 28, 2022
Eating Behavior, Obesity, Appetitive Behavior Trial in London (0 kcal liquid, 600 kcal liquid meal, 1200 kcal liquid meal)
Recruiting
- Eating Behavior
- +2 more
- 0 kcal liquid
- +3 more
-
London, United KingdomPsychoNeuroEndocrinology Research Group, Division of Psychiatry,
Aug 29, 2023
Dental Implant Trial (Implant Type)
Not yet recruiting
- Dental Implant
- Implant Type
- (no location specified)
Oct 11, 2023
Aminoglycoside Dosing Based on PK/PD Characteristics Trial in Jerusalem (Aminoglycoside dose adjustment)
Recruiting
- Aminoglycoside Dosing Based on PK/PD Characteristics
- Aminoglycoside dose adjustment
-
Jerusalem, IsraelHadassah Hebrew University Medical Center
Nov 8, 2022
Pancreatic Tumors Trial in Shanghai (Sofantinib?abraxane?gemcitabine, Abraxane combined with gemcitabine)
Not yet recruiting
- Pancreatic Neoplasms
- Sofantinib、abraxane、gemcitabine
- Abraxane combined with gemcitabine
-
Shanghai, ChinaFudan University ShangHai Cancer Center
Jul 31, 2023
Healthy Volunteers, Anemia, Sickle Cell Trial in Spain, United States (AG-946, AG-946 Matched Placebo)
Recruiting
- Healthy Volunteers
- Anemia, Sickle Cell
- AG-946
- AG-946 Matched Placebo
-
La Jolla, California
- +10 more
Jan 19, 2023
Leukemia, Myeloid, Acute Trial in Worldwide (AG-120, Azacitidine, AG-221)
Active, not recruiting
- Leukemia, Myeloid, Acute
- AG-120
- +2 more
-
Duarte, California
- +72 more
Aug 18, 2022
Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
Not yet recruiting
- HIV Seropositivity
- +2 more
- HIV Ag +Ab Assay Kit (Sysmex)
- (no location specified)
Aug 1, 2023
Metastatic Pancreatic Cancer Trial in Shanghai (Iodine125-Seeds implantation, Gem/nab-P Chemotherapy)
Not yet recruiting
- Metastatic Pancreatic Cancer
- Iodine125-Seeds implantation
- Gem/nab-P Chemotherapy
-
Shanghai, Shanghai, ChinaChanghai Hospital
May 11, 2023
COVID-19 Pandemic Trial (PMC Sure Status COVID-19 Antigen Test, Acon Flowflex COVID-19 Antigen Home Test)
Not yet recruiting
- COVID-19 Pandemic
- PMC Sure Status COVID-19 Antigen Test
- Acon Flowflex COVID-19 Antigen Home Test
- (no location specified)
Nov 21, 2022
Venous Leg Ulcer, Diabetic Foot Trial in Worldwide (AQUACEL® Ag+ Extra™, Cutimed® Sorbact®)
Recruiting
- Venous Leg Ulcer
- Diabetic Foot
- AQUACEL® Ag+ Extra™
- Cutimed® Sorbact®
-
Barranquilla, Colombia
- +13 more
May 26, 2023
Suprasorb® A + Ag in Treatment of Wounds at Risk of Infection
Recruiting
- Pressure Ulcer
- +5 more
- Suprasorb® A + Ag wound dressing and rope
-
Bolesławiec, Poland
- +7 more
Dec 2, 2022
Bioequivalence Trial in Erfurt (Rivastigmine twice-weekly 9,5 mg/24 h, Exelon® 9.5 mg/24 h)
Active, not recruiting
- Bioequivalence
- Rivastigmine twice-weekly 9,5 mg/24 h
- Exelon® 9.5 mg/24 h
-
Erfurt, Thuringia, GermanySocraTec R&D GmbH, Clinical Pharmacology Unit
May 22, 2023
SARS-CoV-2 Antigen RDT Evaluation COVID-19 Antigen Rapid
Completed
- Corona Virus Infection
- The Abbott Panbio™ COVID-19 Ag Rapid Test
-
Gaborone, Gabonone, BotswanaBotswana Harvard AIDS Institute Partnership
Jun 19, 2023